Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 07 2025
0mins
Source: Newsfilter
Oncternal Therapeutics Delisting Announcement: Oncternal Therapeutics plans to file a Form 25 Notification of Delisting with the SEC on March 17, 2025, to remove its securities from Nasdaq after trading was suspended in December 2024. Following this, the company will file a Form 15 to deregister with the SEC, suspending its obligation to file periodic reports.
Company Overview: Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies for cancers with significant unmet medical needs, particularly targeting hematological malignancies and prostate cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
